Mallinckrodt transforms portfolio with sales, acquisitions

In addition to the sale of its nuclear medicine business, Mallinckrodt announced in January that it was selling hemostasis products. It also has been reported that the company is considering a sale of its generic drug unit, a division that accounted for about 30 percent of Mallinckrodt ’s sales in the first quarter of 2017.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news